[Recent Research Advances in Classification and Treatment of Primary Cutaneous Lymphoma--Review]

Primary cutaneous lymphoma (PCL) is a group of heterogeneous diseases. Traditional chemotherapy methods often result in substantial toxic side effects due to their low tumor selectivity. Currently, individualized therapy based on the genetic characteristics and target molecules of tumors constitutes the main treatment strategy for managing PCL. In recent years, research on novel treatment options has developed rapidly. These innovative therapies, which primarily include monoclonal antibodies, immune checkpoint inhibitors, small-molecule inhibitors, and chimeric antigen receptor T-cell (CAR-T) therapies, not only expand the treatment options for patients but also significantly improve their survival outcomes. The objective of this article is to provide a comprehensive review of the latest classification system for PCL and the most recent research advancements in cutting-edge treatment strategies.